495 related articles for article (PubMed ID: 28593446)
21. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
22. De novo C3 glomerulonephritis in a renal allograft.
Nahm JH; Song SH; Kim YS; Cheong HI; Lim BJ; Kim BS; Jeong HJ
Ultrastruct Pathol; 2016; 40(2):112-5. PubMed ID: 26986539
[TBL] [Abstract][Full Text] [Related]
23. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
24. C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB; Bomback AS
Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
[TBL] [Abstract][Full Text] [Related]
25. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
26. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
27. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
28. C3 glomerulopathy in a patient with a history of post-infectious glomerulonephritis.
Nnadi N; Hendricks AR; Torrealba J; Drake KA; Gattineni J
Pediatr Nephrol; 2024 Mar; 39(3):745-748. PubMed ID: 37874356
[TBL] [Abstract][Full Text] [Related]
29. A case of C3 glomerulonephritis successfully treated with eculizumab.
Payette A; Patey N; Dragon-Durey MA; Frémeaux-Bacchi V; Le Deist F; Lapeyraque AL
Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589
[TBL] [Abstract][Full Text] [Related]
30. Eculizumab and recurrent C3 glomerulonephritis.
Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
[TBL] [Abstract][Full Text] [Related]
31. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.
Wong EKS; Marchbank KJ; Lomax-Browne H; Pappworth IY; Denton H; Cooke K; Ward S; McLoughlin AC; Richardson G; Wilson V; Harris CL; Morgan BP; Hakobyan S; McAlinden P; Gale DP; Maxwell H; Christian M; Malcomson R; Goodship THJ; Marks SD; Pickering MC; Kavanagh D; Cook HT; Johnson SA;
Clin J Am Soc Nephrol; 2021 Nov; 16(11):1639-1651. PubMed ID: 34551983
[TBL] [Abstract][Full Text] [Related]
32. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.
Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM
Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376
[TBL] [Abstract][Full Text] [Related]
33. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
34. C3 nephritic factor associated with C3 glomerulopathy in children.
Nicolas C; Vuiblet V; Baudouin V; Macher MA; Vrillon I; Biebuyck-Gouge N; Dehennault M; Gié S; Morin D; Nivet H; Nobili F; Ulinski T; Ranchin B; Marinozzi MC; Ngo S; Frémeaux-Bacchi V; Pietrement C
Pediatr Nephrol; 2014 Jan; 29(1):85-94. PubMed ID: 24068526
[TBL] [Abstract][Full Text] [Related]
35. FHR-5 Serum Levels and
Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
Front Immunol; 2021; 12():720183. PubMed ID: 34566977
[TBL] [Abstract][Full Text] [Related]
36. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
[TBL] [Abstract][Full Text] [Related]
37. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
[TBL] [Abstract][Full Text] [Related]
38. C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition.
Sethi S; Quint PS; O'Seaghdha CM; Fervenza FC; Bijol V; Dorman A; Dasari S; Smith RJ; Kurtin PJ; Rennke HG
Am J Kidney Dis; 2016 Jun; 67(6):949-53. PubMed ID: 26896898
[TBL] [Abstract][Full Text] [Related]
39. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
[TBL] [Abstract][Full Text] [Related]
40. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.
Zhang Y; Nester CM; Holanda DG; Marsh HC; Hammond RA; Thomas LJ; Meyer NC; Hunsicker LG; Sethi S; Smith RJ
J Am Soc Nephrol; 2013 Nov; 24(11):1820-9. PubMed ID: 23907509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
